Myasthenia Gravis Disease Market is estimated to reach USD 2,538.6 million by 2026 from USD 1,012.2 million in 2017. The market is anticipated to grow at a CAGR of 10.8% during the forecast period. Asia-Pacific is bifurcated into China, India, Japan, and Rest of Asia-Pacific. In 2017, North America market was estimated to dominate the market growth due to high occurrence of disease such in North America.
New York, NY -- (SBWIRE) -- 11/20/2018 -- Myasthenia gravis disease is a neuromuscular ailment that causes the weakness of skeletal muscles, that are used for body movement. MG Disease is generally caused by an autoimmune disease when communication between muscles and nerve cells becomes impaired. According to the Myasthenia Gravis Foundation of America, MG is relatively rare condition that affects approximately 14 to 20 out of every 100,000 people in the United States.
Moreover, according to the National Institutes of Health (NIH), MG typically occurs in people over the age of 40 where Women are more likely to be diagnosed as younger adults. There is no exact cure for the MG disease. However, through appropriate diagnosis and medication treatment, the disease can be controlled over the time. The symptoms of the MG disease include facial paralysis, difficulty breathing due to muscle weakness, difficulty swallowing or chewing, drooping of eyelids, and trouble in walking.
Request Sample for more Professional and Technical insights @
https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/request-for-free-sample
The global Myasthenia Gravis Disease market is majorly driven by the factor such as high incidences of neuromuscular disorders. Moreover, increasing number of clinical facilities across the region and rising consciousness about the treatment are other factors driving the market growth. However, the unfamiliarity with early symptoms as well as signs and high cost associated with the treatment are factors hampering the market growth.
The leading companies profiled in the Myasthenia Gravis Disease Market report include: -
- Alexion Pharmaceutical Inc.
- Avadel Pharmaceuticals plc
- CSL Behring
- Grifols S.A.
- Baxter International Inc.
- Shire plc
- Novartis AG
- F. Hoffmann-La Roche AG
- Takeda Pharmaceutical Company Limited
- Valeant Pharmaceuticals International Inc.
For 'Queries' related to this research report, Make an Enquiry @
https://www.polarismarketresearch.com/industry-analysis/myasthenia-gravis-disease-market/inquire-before-buying
The report provides an extensive qualitative and quantitative analysis of the market trends and growth prospects of the Myasthenia Gravis Disease Market, 2017-2026. This report comprises a detailed geographic distribution of the market across North America, Europe, APAC, Latin America, and MEA. North America is further segmented into U.S., Canada, and Mexico. Europe is divided into Germany, UK, Italy, France, and Rest of Europe.
Myasthenia Gravis Disease Market Key Segments: -
Diagnosis:
- Imaging
- Blood Tests
- Electrodiagnostic
- Edrophonium Test
Treatment:
- Medication
- Surgery
- HSCT
End-User:
- Hospitals
- Clinics
- Academic Research Institutes
Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Partial TOC of Myasthenia Gravis Disease Market: -
1. Industry snapshot
2. Ecosystem analysis
3. Market Dynamics
4. Industry analysis - Porter's five force
5. Degree of competition
6. Market PEST Analysis
7. Market Value Chain Analysis
8. Industry Trends
9. Competitive Ranking Analysis